Zydus Lifesciences gets FDA approval for Ivermectin Cream, 1%

Zydus Lifesciences (previously called Cadila Healthcare) has secured final approval for antiparasitic ointment Ivermectin Cream, 1% from the US Food and Drug Administration (FDA).

Ivermectin Cream, 1% is the generic of Soolantra, which is used for treating inflammatory lesions of rosacea.

Zydus Lifesciences will manufacture Ivermectin Cream at its topical manufacturing facility in Ahmedabad, India.

Zydus Lifesciences gets FDA approval for Ivermectin Cream, 1%. Photo courtesy of Zydus Cadila.

As per IQVIA MAT June 2022, Ivermectin Cream had annual sales of 176 million in the US.

Zydus Lifesciences currently has 319 approvals and to date has filed more than 420 abbreviated new drug applications (ANDAs) since the start of the filing process in FY 2003-04.

Ahmedabad, Cadila Healthcare, India, Ivermectin, lesions, rosacea, Soolantra, US FDA, US Food and Drug Administration, USA, Zydus Lifesciences